Isoniazid induces its own resistance in nonreplicating Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2100-2104

  Siddiqi, Salman ^a   Takhar, Param ^a   Baldeviano, Christian ^b   Glover, William ^b   Zhang, Ying ^b  

^a BD Technologies   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; ISONIAZID; KATG PROTEIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; COLONY COUNT, MICROBIAL; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SERIAL PASSAGE;

EID: 34250159090     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00086-07     Document Type: Article

References (22)

1. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. de Lisle, and W. R. Jacobs, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
2. Barnett, M., S. Bushby, and D. Mitchison. 1953. Isoniazid-resistant strains of tubercle bacilli. Their development and stability. Lancet i:314-320.
3. Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, N. K. Menon, D. A. Mitchison, N. Rist, and N. A. Smelev. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. W. H. O. 41:21-43.
4. Cohn, D. L., F. Bustreo, and M. C. Raviglione. 1997. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin. Infect. Dis. 24(Suppl. 1):S121-S130.
5. Reference deleted.
6. Espinal, M. A. 2003. The global situation of MDR-TB. Tuberculosis 83:44-51.
7. Lee, A., A. Teo, and S. Wong. 2001. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 45:2157-2159.
8. Middlebrook, G. 1954. Isoniazid resistance and catalase activity of tubercle bacilli. Am. Rev. Tuberc. 69:471-472.
9. Miesel, L., T. R. Weisbrod, J. A. Marcinkeviciene, R. Bittman, and W. R. Jacobs, Jr. 1998. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 180:2459-2467.
10. Rawat, R., A. Whitty, and P. J. Tonge. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. USA 100:13881-13886.
11. Rozwarski, D. A., G. A. Grant, D. H. Barton, W. R. Jacobs, Jr., and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102.
12. Shoeb, H. A., B. U. Bowman, Jr., A. C. Ottolenghi, and A. J. Merola. 1985. Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 27:404-407.
13. Siddiqi, S. H. 1992. Antimicrobial susceptibility testing: radiometric (BACTEC) tests for slowly growing mycobacteria, p. 14-25. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. ASM Press, Washington, DC.
14. + ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob. Agents Chemother. 49:708-720.
15. Viveiros, M., I. Portugal, R. Bettencourt, T. C. Victor, A. M. Jordaan, C. Leandro, D. Ordway, and L. Amaral. 2002. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2804-2810.
16. World Health Organization. 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. World Health Organization, Geneva, Switzerland.
17. Winder, F. 1982. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria. In C. Ratledge and J. Stanford (ed.), The biology of mycobacteria. Academic Press, New York, NY.
18. Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.
19. Zhang, Y., T. Garbe, and D. Young. 1993. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol. Microbiol. 8:521-524.
20. Zhang, Y., and A. Telenti. 2000. Genetics of drug resistance in Mycobacterium tuberculosis, p. 235-254. In G. Hatfull and W. R. Jacobs (ed.), Molecular genetics of mycobacteria. ASM Press, Washington, DC.
21. Zhang, Y. 2004. Isoniazid, p. 739-758. In W. N. Rom and S. M. Garay (ed.), Tuberculosis, 2nd ed. Lippincott Williams & Wilkins, New York, NY.
22. Zhang, Y., C. Vilcheze, and W. R. Jacobs. 2005. Mechanisms of drug resistance in Mycobacterium tuberculosis, p. 115-140. In S. T. Cole, K. D. Eisenach, D. N. McMurray, and W. R. Jacobs, Jr. (ed.), Tuberculosis and the tubercle bacillus, 2nd ed. ASM Press, Washington, DC.